http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Sep 2025 11:59:41 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/Investing/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html <p>Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. <br /><br />Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.</p> <p>IQVIA is now our top pick, Jefferies said, pointing to stronger client wins and steadier business trends. <br /><br />The firm highlighted that IQVIA’s lower reliance on any single customer makes it more resilient to ongoing pharmaceutical restructurings. Jefferies raised its price target on the stock to $225.</p> <p>ICON, by contrast, faces “too many headwinds to recommend buying,” the note http://www.streetinsider.com/General+News/Jefferies+backs+IQVIA+and+Charles+River%2C+cuts+ICON+on+customer+losses/25314119.html Tue, 09 Sep 2025 11:59:41 -0400 CRL FTRE ICLR IJF IQV MEDP QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/Press+Releases/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/PRNewswire/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/PRNewswire/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/PRNewswire/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/PRNewswire/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS http://www.streetinsider.com/PRNewswire/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.phldph" idsrc="xmltag.org" >PHILADELPHIA</location></span>, <span class="legendSpanClass"><chron>Sept. 4, 2024</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.signanthealth.com/" target="_blank" rel="nofollow"><span>Signant Health</span></a>, the leader in evidence generation for modern clinical trials, announced today it has joined <span value="ACORN:5020019328" idsrc="xmltag.org" >IQVIA</span>, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. </p> <p><a target="_blank" href="https://www.iqvia.com/onehome" target="_blank" rel="nofollow"><span>IQVIA One Home for Sites</span></a> is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, http://www.streetinsider.com/PRNewswire/Signant+Health+expands+availability+of+its+eClinical+solutions+by+joining+IQVIA+One+Home+for+Sites+initiative/23684606.html Wed, 04 Sep 2024 09:00:00 -0400 A.50200193 IQV IQV IQVH O.11181775 O.36700628 QTS QTS